BRAF and thyroid cancer: Taken together, administration of a BRAF/MEK inhibitor not only increases RAI delivery to target lesions but also may contribute to increasing radiosensitivity to augment 131I therapeutic efficacy in thyroid cancer carrying RAS or BRAF mutations.